The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...
C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.
Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with PAH.
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
The trial was launched by King’s College London following the UK’s ban of puberty blockers in under 18s. Image credit: Dmitry Demidovich / Shutterstock.com An investigator-led trial that is ...
The Phase I trial aims to assess tolerability, activity, and safety of ZI-MA4-1 in patients with advanced cancers. Credit: Inna Dodor / Shutterstock.com. Zelluna has received the UK Medicines and ...
Around 89% of eligible participants completed the therapy through week 140. Credit: Gorodenkoff / Shutterstock.com. Johnson & Johnson (J&J) has reported new findings from the QUASAR long-term ...
Bayesian statistical models use prior data to update the probability of a hypothesis as new evidence emerges. Image credit: PeopleImages / Shutterstock.com Bayesian statistical models could help ...
Prasad and Makary disagree that some may believe this move to just one pivotal trial shows the FDA relaxing its standards.
NeuroSense will advance the candidate to Phase III trials. Image credit: Phalexaviles / Shutterstock.com NeuroSense’s amyotrophic lateral sclerosis (ALS) therapy has improved survival in a Phase IIb ...
Compass will now seek approval for COMP360 in TRD, which could become the first classic psychedelic to gain the FDA’s ...
Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown durable clinical and endoscopic efficacy in a Phase IIb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results